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Sontatic gene therapy is a potentially useful strategy
for the delivery of growth factors or cytokines to
enhance wound healing. Experintental excisional and
incisional wounds in impaired-healing diabetic ntice
(dbldb) were treated with aFGF and with a plasntid
coding for aFGF. A eukaryotic expression plasntid
composed of the Hst signal peptide sequence in-
frante with the human aFGF sequence was used.
Transfection of tissues was accontplished either by
direct plasmid uptake or by uptake facilitated with
cationic liposomes. The results show that the closure
of excisional wounds was significantly accelerated
(p < 0.05) by topical application of human recontbi-
nant aFGF or by transfection with the aFGF plasmid
but not by vehicle or control plasmid not containing
the aFGF sequence. In incisional wounds, aFGF or
transfection with the plasmid significantly increased
A cidic fibroblast growth factor (aFGF or FGF-1) isone of the most promising cytokines for treatingimpaired wound healing. aFGF is a short polypeptidethat influences the general proliferative capacity of awide range of mesoderm- and neuroectoderm-de-
rived cells ;/1 1/;11'0 and is also a potent angiogenesis inducer ;/1 1/;/10
(Imamura el ai, 1990; Mason, 1994). In rats and mice, exogenously
applied aFGF promoted healing of full-thickness dermal wounds
and produced a transient increase of tensile strength in incisional
wounds (Mellin et ai, 1992, 1995). Applications of aFGF have been
limited, however, because of the necessity to administer relatively
large amounts of recombinant aFGF that is often blocked fi'om
reaching the target tissue by eschar. The short half-life of aFGF is
another drawback of topical application that necessitates fi'equent
dosing (Gutierrez el ai, 1992). Frequent application of aFGF with
high doses to overcome diffusion problems can be costly.
Somatic gene therapy is an approach that may overcome these
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transcription-coupled polymerase chain reaction.
the wound-breaking strength compared to their cor-
responding controls (p < 0.05). Quantitative histol-
ogy of the plasntid-treated incisional wound sections
revealed improved wound quality. The transcription
of ntRNA from human aFGF cDNA in the incisional
wound tissue extracts was confirmed by RT-PCR,
and the expressed aFGF was detected by intmune dot
blot and immunohistochemistry assays. The transfec-
tion was a transient process with a peak at 9 din dbl+
(littermates of the diabetic mice) incisional wounds,
at 36 d in dbldb incisional wounds, and at 27 d in dbldb
excisional wounds. Cells transfected with human
aFGF occupied up to 6.4% of the transectional area in
the wound sites. Thus, aFGF gene delivery resulted in
both gene expression and a functional improvement
in healing. Key words: getle t1lel'apJ,ldiabetic lIlicelcytokitle
e~1'ressiotl. ] Il1vest Derlllato[ 108:313-318, 1997
problems. Skin wounds represent an attractive target for therapeu-
tic gene manipulation because wounds are readily accessible. Major
skin-cell types (such as fibroblasts, keratinocytes, and endothelial
cells) are usually easy to infect with currently used vectors (Krueger
el ai, 1994). Skin cells are highly responsive to the aFGF timulus,
and the results are easy to observe (Krueger el 01, 1994). To
establish a practical somatic gene therapy for wound healing, this
study was designed (i) to use recombinant human aFGF to dem-
onsU'ate its therapeutic effect on wounds in genetically healing-
impaired diabetic mice, (ii) to apply a plasmid containing an insert
of human aFGF cDNA to the wounds and to confirm the ;1/ 1/;1/0
transcription and translation of the aFGF cDNA, and (iii) to
determine whether the expressed aFGF can result in a local effect
with potential therapeutic significance.
MATERlALS AND METHODS
Construction of the Expression Vector for aFGF Thc plasmid
pMEXnco-sp-aFGF, which is composed of thc eDNA for human signal
pcptide and human aFGF, was a gift from X. Zhan and T. Maciag, American
Red Cross, Rockville, MD (Forough et 01. 1993). Briefly, an !lSI signal
peptide (sp) scquence was joined in-frame at the 5' end of the aFGF cDNA
to facilitate the secretion of the peptide, and the full-length cDNA of the
sp-aFGF was constructed between the restriction sites of Sail and EcoRl in
the plasmid pMEXneo. A Kozak sequence with the initial codon within it
preceded the 5' region of the sp-aFGF eDNA for maximal cukaryotic
translation efficiency. A sequcnce of murinc sarcoma virus long terminal
repeat and a simian virus 40 polyadenylation site werc, rcspectively, located
up- and downstream of the insert (Fig 1). The pMEXneo plasmid without
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Primer set 1: Signal peptide Human-aFGF .
~
~
Primer set 2: Signal peptide Human-aFGF .
•
Figure 1. Construct of pMEXlleo and schematic diagram of the
priming site of two primer sets. The signal peptide-aFGF (sp-aFGF)
cON A was inserted between tbe SolI and EwRl restriction sites to form
pMEXneo-sp-aFGF.
tbe insert was prepared by double digestion witb SoiI/EcoRI. gel purifica-
tion of the large fi'agment, then blunting, and ligation of tbe ends of the
linear plasmids with mung bean nuclease and T4 ligase.
aFGF and aFGF cDNA Delivery to Excisional Wounds The exper-
iments reported berein were conducted according to the principles set forth
in tbe Cllide for i"e Core olld Use of LO/JlII'OIOll' Allilllois ('1985). Genetically
bealing-impaired female diabetic mice (8-wk-old C57BLlKsj dlJldb, from
The jackson Laboratory, Bar Harbor, ME) that exhibit several characteris-
tics of human adult-onset diabetes, including obesity and markedly delayed
wound closure, and arc widely accepted as an ill "i"o model to study wound
bealing (Greenhalgh et 01, 1990; Brown et 01, 1994; Sun el 01, 1996) were
used to evaluate tbe ill ,Ji"o effect of aFGF and aFGF cDNA. A single
full-thickness 6-mm diameter (0.28 cm 2) excisiona! wound was made on the
mid-dorsum with a biopsy puncb (Acuderm Inc., Ft. Lauderdale, FL) and
left undres cd. In each experiment, groups of five animals were treated witb
eitber 1.0 J.Lg of buman recombinant aFGF (GIBCO BRL, Gaitbersburg,
MD) in J 0 J.LI of pbospbate-buffered saline (PBS) containing 0.3 J.Lg of
beparin or tbe PBS vebicle as control once daily for 15 consecutive days
after wounding (two experiments). For gene therapy groups, 2.5 J.Lg of
pMEXneo-sp-aFGF in 10 J.LI of a Lipofectamine/Dulbecco's modified
Eagle's medium (1 :1, vol/vol) mixture witb 0.3 J.Lg of beparin or 2.5 J.Lg of
pMEXneo in 10 J.LI of Lipofectamine/Dulbecco's modified Eagle's medium
(1 :1) mixture (as a control) were topically applied to tbe wounds once daily
for three consecutive days after wounding (five experiments), Scabs were
gently removed on days 3, 5, 7, 9. 11, 13, and 15 after wounding to
accun'tely visualize the wound margin and to facilitate access of tbe tested
reagent to tbe wound. The wound area was recorded and analyzed at 1 b
after wounding (day 0), on day 1 and alternate days thereafter by using an
image analysis system (BioScan Inc., Edmonds, W A).
Application of aFGF and aFGF Gene to Incisional Wounds The
diabetic animals were divided into ten groups of five mice, and a linear
incision 2 cm long was made transversely on tbe shaved dorsum and closed
by sutures. In the aFGF groups, eacb mouse in two groups of mice received
1.5 J.Lg of buman recombinant aFGF in 15 J.Ll of PBS containing 0.3 J.Lg of
heparin once daily for 12 d (5 J.LI topical on incision margins and 10 J.LI
injected subcutaneously at tbe base of tbe incision) and another two groups
of mice received only PBS containing beparin as control (two experiments).
In the aFGF gene groups, each mouse in tbree groups of mice received 130
J.Lg of pMEXneo-sp-aFGF in 35 J.LI of PBS witb 0.3 !J.g of heparin (5 ILl
topical on wound margin and 30 J.LI injected subcutaneously at tbe base of
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tbe incision). and each mouse in another three groups received 130 ILg of
pMEXneo (as control) once daily for 12 d (three experiments). All groups
treated with aFGF or PBS, one group treated witb pMEXneo-sp-aFGF, and
one group treated with pMEXneo plasmjd were sacrificed on day 17 after
\vollnding. The rClnaining groups \vcrc sacrificed on da)7 27 after wounding.
Tbe wound strip was excised from the dorsal skin and cut into an
8-l1l1n-widc strip by using a tClnplatc. Breaking strength \\1;15 1'11easured
immediately after excision by using a custom-made tensiometer. Tension
was applied at a constant rate of 'I cm/min by using a 1.0-kg force
transducer. Breaking strength, the point of maximal stress before wound
separation, was recorded and analyzed on a computer supplied with
custom-made software.
To prevent disturbance of wounds by licking. all animals were individ-
ually housed after wounding,
Reverse Transcription-Coupled Polymerase Chain Reaction (RT-
PCR) Assay of the aFGF Gene Transcription To examine the
tr:lI1scription of sp-aFGF cDNA in the db/db incision specimens harvested
27 d after wounding, total RNA was extracted from the tissue and digested
with RNase-free DNase (GlDCO BRL, Gaithersburg, MD). Then, RT-
PCR was performed according to the protocols provided b)' manufacturer
(Invitrogen, San Diego, CA). Two primer sets were designed (Fig 1):
primer set 1 for amplifying the full-length human aFGF sequence (sense
sequence,S'-ATGGCTGAAGGGGAAATCACCACCTTCACAGCCCT-
3'; antisense sequence, 5 'TTAATCAGAAGAGACTGGCAGGGGGAG-
AAACAAGA-3') and primer set 2 for the spticed full-length sequence of
tbe signal peptide and human aFGF (sense sequence, 5'-GGGAGAC-
CGTCTAGATGGCGGGGCCCGGGACGGC-3'; antisense sequence, 5'-
GTCGACCTTAAGTTAATCAGAAGAGACTGGCAGGGG-3').
Dot Blot Assay of the Expression Product of the aFGF Gene The
skin margin along the incisional wound treated with pMEXneo-sp-aFGF
was harvested, trimmed to about 3 mm in width, chopped into small pieces
in a dry ice box. homogenized at 4°C in NaCIITris(hydroxymethyl)amin-
omethane (Tris) buffer (pH 7.6) in the presence of 100 J.Lg of phenybnetll-
ylsulfonyl fluoride per ml and 2 ILg of aprotinin per ml (Sigma, St. Louis,
MO), and centrifuged at 10,000 X g for 20 min. The supernatants were
centrifuged with Centricon 100 (Amicon, Danvers, MA) at 1000 X g to
remove molecules larger than 100 kDa and then concentrated with a
Centricon 3. The skin containing the incision treated with pMEXneo only
and a piece of normal skin from each animal were harvested, processed
identically, and used as controls 1 and 2. respectively. Immune dot blot wa
perfon1led with 3 or 6 ILl of ti,e concentrated filtrate with an equivalent
amount of protein (1 ILg/ ILl) loaded on nitrocellulose filters (Millipore,
Bedford, MA). The blots were probed with polyclonal antibodies (R & 0
Systems, Minneapolis. MN) against bovine aFGF and developed according
to the manuf.,cturer's instructions (Vector Laboratories, Burlingame. CA).
Inlmunohistochel11ical Assay of the Gene Transfection Efficiency
and Morphometric Assay of Wound Healing To determine the time
course of gene transfection efficiency, the diabetic mice and their lean
littermates (C57BL/Ksj diJ/+, The jackson Laboratory, Bar Harbor, ME)
were used, A full-thickness excisional or incisional wound was made and
treated with pMEXneo-sp-aFGF or pMEXneo as described above. The
wound was harvested at the designed intervals, fixed in 10% neutral-
buffered formalin for 24 h, embedded in paraffin. and sectioned at 5 J-Lln
thickness. After being deparaffinized and rehydrated in water, the sections
were digested with 0.1% trypsin for 1 h, blocked with goat nonimmune
serum for 20 min, probed witb the primary antibodies. and stained with Fast
Red by following the procedures of the manufacturer (Sigma, St. Louis,
MO). The tissue sections were observed with a Nikon Optiphot microscope
with a color vidco cmTIera connected to an inlage analysis systcnl. Thc ill
/li/lo transfection efficiency of the aFGF gene was defined in the following
way: under the X40 objective lens, the region of cell transfection adjacent
to tbe wound was located and the anti-aFGF stained areas were measured in
sample areas by setting the threshold range of the red staining color. The
transfected areas were then expressed as percentages of the sampled areas.
The value of the transfection efficiency is the mean of measurements from
two fields per section of two sections per incision or excision wound from
three or four mice in each group. An image analysis system was used to
evaluate transectional scar area. cellular density, hair follicle number, and
dermal thiclO1ess as measures of tllC quality of wound heaung.
Statistical Analysis Data are presented as means ± SO except where
indicated. Statistical analysis of the data were performed by using the
one-way analysis of va,;ance test with significance at 0.05 level.
RESULTS
Acceleration of Healing by aFGF or aFGF Gene The exog-
enous application of aFCIO improved healing of full-thickness skin
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Table I. Time Course of Effects of aFGF and aFGF cDNA on Wound Areas"
Day after aFGF PBS Control aFGF cDNA Control cDNA
Wounding (% control") (111m 2) n'- (% control") (mil}) nIl
1 101 :!: 4 36.4 :!: 3.2 10 100 :!: 2 30.5 ± 1.2 ?--:>
3 97 ± 6 36.5 ± 3.5 10 100 :!: 3 32.6 ± 1.2 25
5 78 :!: 13 37.2 ± 2.6 10 94 :!: 3 32.3 :!: 1.2 25
7 78 ± 12 28.6 ± 3.5 10 103 ± 6 24.3 ± 1.4 25
9 6'1 :!: 12" 22.9 :!: 3.4 10 106 ± 12 16.1 :!: 1.1 25
11 62:!: 12" 16.5 :!: 3.4 10 79 :!: 11 10.7:!: 0.8 25
13 48 :!:11'" 15.0 :!: 3.0 10 56 ± 9" 8.8 ± 1.0 25
15 28:!: 8" 10.8±2.9 10 42 :!: 7" 5.3 :!: 0.8 25
Q Wound areas were measured in <11';,1/, mOllSe excision wounds treated with 1.0 f-Lg of human recombinant aFGF (aFGF), PBS (control of aFGF group), 2.5 f-Lg of
pMEXneo-sp-aFGF (aFGF eDNA), or 2.5 f-Lg of pMEXneo (control eDNA. control of aFGF eDNA group).
" MC:Jl1s ::!: SEM of the woulld arC;lS were expressed as a pCl'ccn[<Igc of the arc:JS of control wounds.
(' Number of mice ill each group (11l1l11;l1l recombinant 3FGF or PBS C0l1tro1).
,I Number of mice ill each group (pNIEXllco-sp-aFGF or pMEXllCO). Each control or cxpcrimcn[n! group consisted of five animals per cxpCrimCI1L



















sp-aFGF 0.22 ± 0.09"
pMEXneo 0.75:!: 0.39
Table II. aFGF cDNA Improves Wound Healing and
Wound Quality"
" Tissue sccrions were from incisiollill wounds ofdb/db mict.' harn~stcd nt d:ty 27 after
I-he wound and quantified by C01l1lHltCr-assislcd image ;1l1alysis:ls dC!ricrihcd in J\/mcri"ls
ml(l !\ft>,hc1ds. The vailic is thc mcan ± SO ofrwo scnions per animal offlvc mice ill Ihe
experimental or conn·ol groups.
/, p < 0.05. compared to corresponding cOlltro!.
controls (Fig 3B,D), Image analysis of the tissue sections revealed
that the transfected wounds had a significantly smaller mean
transectional scar area, higher cellular density, more hair follicles in
the wound sites. and a tendency toward a thinner dermal layer and
a more nearly normal complement of fat cells (Table II, Fig 3).
Transcription of sp-aFGF cDNA I" Vivo The transcription of
human aFGF in the incisional wound tissue extracts was demon-
strated by RT-PCR using two primer sets. The human aFGF
I11.RNA and the sp-aFGF chimeric mRNA were detected ;tI 11;110
(Fig 4, Illites 4,5) but only in transfected wounds. Neither the Hst
signal peptide nor human aFGF should exist in a mouse. We
considered the possibility that the pMEXneo-sp-aFGF plasmid
injected into tlle wounds might be can'ied over to the tissue extracts
and amplified in the RT-PCR, resultiug in a falsc positive, even
though there was a 15-d period betwcen termination of the
injection of pMEXneo-sp-aFGF DNA and harvesting of the tissue
for the RT-PCR. When peR was performcd in the abscnce of
reverse t:ranscriptase, however, therc was no detectable amplifica-
tion of sequcnces in the tissuc cxtract from pMEXneo-sp-aFGF-
treated wounds (Fig 4, Intle 3), indicating that there was no residual
sp-aFGF DNA contamination in the extracts of pMEXneo-sp-
aFGF-treated wound tissue.
Translation of sp-aFGF cDNA I" Vivo and the Time Course
of Gene Transfection Efficiency Immune dot blots of wound
tissue extracts showed a hcavily stained dot in extracts of pMEX-
neo-sp-a FGF-treated wounds, but little stain in the control (Fig 5).
Immunohistochemistry of transfected wound tissues revealed that
transfected cells with red st~lining in the cytoplasm area appeared in
distinct clusters of a few cells (Fig 6). Cells in the dermis and
subcutaneous laycr adjaccllt to the wound were transfected, but
cells in distal skin wcre not (Fig 3A,C). Fibroblasts were the main
cell type that expressed human aFGF, and keratinocytes in the basal
layer werc occasionally observed with red staining. The image
analysis of the tissue sections stained with antibody to aFGF showcd





















excisional wounds. Two effects of aFGF on wound healing were
observed in excisional wounds. (i) aFGF enhanced the sealing of
the wound edge to the underlying tissue, (ii) aFGF accelerated the
rate ofclosure of the wouuds from days 3 to 15 after wounding with
a statistically significant (p < 0.05) improvement at day 9 and
thereafter until closure was achieved (Table I). In incisionaJ
wounds, a significant (p < 0.05, compared to controls) increase of
wound-breaking strength was observed in skin wounds treated
with aFGF and harvested at day 17 after wounding (Fig 2). Thus,
aFGF was an effective healing enhancer. The excisional wounds
treated with pMEXneo-sp-aFGF showed an accelerated healing at
days 13 and 15 after wounding (p < 0.05) compared to controls
(Table I). lncisional wounds treated with pMEXneo-sp-aFGF had
a significant increase in breaking strength in the wounds harvested
at day 27 after wounding (p < 0.05) but not in the tissue strips
harvested at day '17 after wounding when compared to their
corresponding controls (Fig 2). The histology of the excisional and
incisional wounds treated with pMEXneo-sp-aFGF and harvested
at day 27 after wounding revealed a well-differentiated dermis with
many hair follicles (Fig 3A,C) compared with their corresponding
Figure 2. hnprovement of breaking strength of incisional wounds
treated with aFGF and pMEXneo-sp-aFGF. OJ'('I/ b",.. treated with Pl3S
as control of aFGF group; nCl/scI)' bllfcben b",., treated with 1.5 JLg; of human
recombinant aFGF in PBS daily for "\2 d; I",(rben b",.s, treated with 130 /Lg
of pMEXneo without aFGF insert (control of pMEXneo-sp-aFGF group);
cross-I"'teben b",.s. treated with 130 JLg ofpMEXneo-sp-aFGF daily for 12 d.
., Statistic;t1ly significant (I' < 0.05).
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Figure 3. Histology ofpMEXneo-sp-aFGF treated wounds. (A) and (C), Excisional and incisional wounds, respectively, treated with pMEXneo-sp-
aFGF. (B) and (D), Excisional and incisional wounds, respectively, treated with pMEXneo (as controls of (A) and (C) . • , incision sites; . aFGF
immunostaining; a, hair follicle. Scale bars, 200 /.I-m.
increased transfection to a peak that depended on the strain of
mouse (Table III). The incision wounds of diabetic mice achieved
the highest mean transfection percentage, 6.4% of the sampled area
at 36 d.
DISCUSSION
aFGF eDNA Mitnicked the Effect of aFGF Peptide on
Wound Healing Delivery of the pMEXneo-sp-aFGF plasmid to
wounds led to the transcription and translation of the human aFGF
gene and, most importantly, promoted excisional and incisional
wound healing by the criteria of wound area, wound strength, and
histology similar to the effect of recombinant human aPGF on
healing. The improvement in scar area, cellular density, and hair
folHcle numbers suggests a relationship between acceleration of
wound remodeling and improvement of the quality of wound
healing in pMEXneo-sp-aFGF-treated wounds. This study and the
reports of Mellin and colleagues (Mellin et ai, 1992, 1995) show
that recombinant aFGF improves skin healing in mice or rats. The
effect in both rats and mice may result from the strong mitogenic
effect ofaFGF i/l. vivo (Dabin and Courtois, 1991; Fitzpatrick et ai,
1992; Matuszewska et ai, 1994) and ill lIitro (Chen et ai, 1991·




Figure 4. Transcription of aFGF eDNA ill "i"o. Lane 1, normal mouse
skin extracts amplified with primer set 1 (directed to the aFGF sequence);
lalle 2, extracts of wounds treated with the control pMEXneo and amplified
with primer set 1; lalle 3, tissue extract of the wounds treated with
pMEXneo-sp-aFGF and amplificd with primer set 1 but without reverse
transcriptase; Imle 4, tissuc extract of the wounds treatcd with pMEXneo-
sp-aFGF and amplified with primer set 2 (directed to the sp-aFGF fusion
sequence); lalle 5, tissue extract of the wounds treated with pMEXneo-sp-
aFGF and ampl.ified with primer set 1; lalle 6, DNA size ladder.
c
Figure 5. Translation of aFGF eDNA ill "i"o. Immunoassay of wound
tissuc extracts. Rows A-C, tissue extract of wounds treated with pMEXneo-
sp-aFGF, pMEXneo, and normal tissue, respectively. COIIIIIIII 1, 3 /.I-g of
total protein extract; COIIllIlIl 2, 6 /.I-g of protein.
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Figure 6. Immunohistochemistry of human aFGF expression. Immunohistochemistry with antibody to aFGF, developed with Fast Red. (A) Tissue
section of an incisional wound from a db/db mouse treated with pMEXneo-sp-aFGF and harvested at day 27 after wounding. (B) Tissue section from a db/db
mouse treated with pMEXneo (as control of (A). An'OII1S indicate examples of aFGF staining. Scale bars, 20 Jolm.
60% sequence homology with aFGF and shares the capacity to
stimulate proliferation in endothelial cells and fibroblasts, improved
healing in diabetic mice (Greenhalgh et aI, 1990; Tsuboi and Rifkin,
1990). The healing process in inlpaired-healing diabetic mice is
complex and responsive to many different cytokines (Greenhalgh et
aI, 1990; Roemar and Friedmann, 1992; Brown et aI, 1994), perhaps
acting in a concerted temporal and spatial network.
The natural structure of the aFGF gene translation product does
not possess a classical secretory signal sequence (Burgess et 01,
1986), and in recent years there has been considerable debate
concerning its ability to be secreted at all. Current opinion,
however, is moving away from the idea that this molecule is only
released from the cell when the integrity of the plasma membrane
is compromised, as evidence is accumulating to suggest that it is
released from the cell by novel secretory mechanisms Oackson ef aI,
1992; Mignatti et ai, 1992; Mason, 1994). Because the ability of
aFGF to be secreted cannot be simply predicted, we used, in tlus
study, a plasmid with the insert of the full-length aFGF sequence
and a signal peptide sequence joined in-frame at the 5' end of the
aFGF fragment. The transformation of cells ill vitm induced by
pMEXneo-sp-aFGF in tlus study (data not shown) and in the work
ofForough and colleagues (Forough et 01,1993) demonstrated tllat
a secretable form of aFGF was expressed in cell culture, which
provided biochemical evidence to explain the acceleration of
wound closure and the increase in breaking strength il/. IIivo.
Table m. III Vivo Transfection Efficiency"
Days Incisionb (db/ +') Incisionb (db/db") Excision' (db/db")
after
Wounding Are.! (%) n'" Area! (%) n C Area! (%) n'
1 o ± 0 3 o± 0 3
2 0.2 ± 0.1 3 O±O 3
3 0.8 ± 0.5 3 0.1 ± 0.0 3
5 1.5 ± 0.7 3 0.8 ± 0.6 3
9 2.6 ± 1.0 3 1.2 ± 0.3 3
18 1.2 :!:: 0.8 3 5.0 ± 1.3 3 3.6 ± 0.7 3
27 1.0 ± 0.2 3 6.3 ± 0.6 3 4.9 ± 1.0 3
36 1.1±0.4 3 6.4 ± 0.2 3 2.8 ± 0.4 3
45 0.8 ± 0.1 3 4.8 ± 0.4 4
(I Transfecrion efficiency is defined as the area occupied by cells that express aFGF
staining as a percellr ofdle total field area. Fields averaged 24,302 ± 4,956 Io'm2 in size.
b Full-thickness incisional wound was treated with 130 J-l.g ofpMEXnco-sp-aFGF in
PBS daily for 12 days.
'Littennates (C57BLlKs] db/+) of dlC diabetic mice.
" Diabetic mice (C57BLlKs] db/db).
~ Full-thickness cxcisional wound was treated with 2.5 J.Lg ofpMEXneo-sp-aFGF in
Lipofectamine/Dulbecco's modified Eagle's medium mixture daily for 3 days.
f Means ± SEM of the transfected areas were from two fields per section of two
sections per animal of all mice in cach group.
A Number of micc in thc experimental or control groups.
It has been hypothesized that impaired wound healing may result
from lack of adequate stimulation by growth mctors. In fact,
growth factors have been used in clinical n;als to test whether they
can improve wound closure in patients with chrOJuc nonhealing
wounds (Brown ef ai, 1991; Robson et aI, 1992; Steed et ai, 1992).
Cytokine gene therapy may overcome some of tile shortcomings of
direct application of the growth factors. For example, gene therapy
encourages a continual supply of growtll factor that is well dis-
persed within the wound site. That steady synthesis declines as tile
wound matures. Also, the gene product would be glycosylated by
host glycosylases and dispersed deep into the wound tissue, rather
than superficially. Particle-mediated transfection of hum3.ll epider-
mal growth factor into porcine skin wound cells led to epidennal
growth factor tr3.llSCriptiOl1 and translation in the wound and
resulted in a significant reduction in leaching ofprotein into wound
fluid, a measure ofreepithelialization (Andree et 01,1994). Cytokine
gene delivery into living animals has been shown to produce
specific systemic inlmunologic effects (Raz et ai, 1993; Wang et 01,
1993), to induce antitumoral activity (Colombo et 01,1991), 3.Ild to
modify neuronal physiology (Federoff et 01, 1992). Gene expression
in muscle tissue after irljection of plasnud cDNA has been demon-
strated in expermlents using reporter gene constructs (Wolff et ai,
1990; Barr and Leiden, 1991; Danko et 01, 1994). Thus, transfection
with genes tailored to a specific healing deficit may permit im-
provement of healing impaired by that deficiency, such as insuffi-
cient vascularization or inadequate keratinocyte proliferation.
Technical Aspects of Gene Therapy for Wound Healing
Based on the characteristics of impaired-healing or nonhealing
wounds, the strategy for application of somatic gene therapy to
wound healing may differ from that currently used for therapy of
cancer or inbom errors of metabolism (Anderson, 1992; Roemer
and Friedmann, 1992; Greenhalgh et 01, 1994; Krueger et ai, 1994).
Plasmids as a vector have substantial adv3.lltages for gene delivery
for wound healing. The plasnuds are easy to manipulate, C3.l1 accept
large inserted sequences, and can be produced stably and cheaply to
a lugh level of purity. By comparison, tbe vectors derived from
retroviruses or adenoviruses are not recommended in wound-
healing management because of potential contamination of repli-
cation-competent wild-type virus in the stock of replication-
defective recombinant virus, tile integration of we transferred gene
into the host genome, and a potential insertional mutagenesis that
may trigger cell tr3.llsformation or even neoplasia (Anderson, 1992;
Gutierrez et 01; 1992; Mulligan, 1993; Vile and Russell, 1994). In
tlus study, the transfection efficiency obtained from the incisional
wounds indicated that even without selection pressure or any agent
to facilitate the transfection, plasmids injected directly to the wowld
tissue resulted in not only a cell transfection ill villo but also an
effective biologic response.
Sinlplicity should also be considered as an inlportant component
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of the stl·ategy. For example, topical application or injection of the
expression plasmid directing the synthesis of the desired cytokine
will obviate the need to express, purify, and administer the
recombinant cytokine protein. Likewise, simple injection of the
plasmid is more easily adapted to clinical use than alternative
mcthods that might rely on stability of a virus vector or of a
eukaryotic cell graft. The results of this study showed that either
topical application or injection arc effective and practical as gene
delivery methods.
In the ideal case, the expression of the applied gene should be
limited to the time required for the wound to hcal. This goal may
be reached in two ways: by using plasmid or by using heterologous
(or modified) genes. Once transfected into mammalian cells,
plasmids will remain extrachromosomal as non replicating epi-
somes. The plasmids will be passed to daughter cells at cell division,
diluted after repeatcd mitoses of the transfected wound cells, and
eventually lost. A weak immune response may eventually inactivate
the xenogeneic gene expression and remove the cells expressing
the gene product. The histology of the transfected wounds revealed
that the highest level of exprcssion of human aFGF was located in
the normal tissue adjacent to the wounds rather than the rapidly
growing wound tissue itself (see Fig 3). This observation suggests
that the cells in the middle of the wounds proliferated after the
pMEXneo-sp-aFGF sequence had been deleted, consistent with the
decrease in the number of the transfected cells. In addition, the
transfection process was transient, with a slow start and an eventual
decline, regardless of the strain of micc, wound type, doses of the
aFGF cDNA, and delivery method.
The prospect of genetic manipulation to effect a curc is contro-
versial but may have advantagcs in specific situations such as
chronic human wounds or inadequate patient compliance. The
cnhancement of healing ill these animal models should encourage
further investigation for eventual clinical application.
NOTE ADDED IN PROOF
A reccnt report found that transfcction of murine wounds with pMEX-nco-
sp-aFGF incrcascd ill vivo keratinoc)'tc proliferation in thc wound sitc as
measured immuI1ohistochemically aftcr incorporation of broll1odeoKyuri-
dinc (Xu L, Sun L, Harmon JW, and Nielscn TB: Transfcction of murinc
cutaneous wounds with aFGF Plasmid. SIII;r:iwl FOI'I//II XLVII:699-702.
1996). This obscrvation suggcstS that a part of thc mcchanism of acrion of
thc plasmid ma)' bc stimlllation of cpitheliaUzation of the wOllnd.
~lIe gmttjilily nclwolIJledge Dr. X. ZIInll nllli Dr. T. Mnciag (Depnrt'lIelll cif
A10lewlnr Biology, Jero/lle H. Hol/alld LnbomlolY for tile Bio/lledicnl Sci/'IIC/'S,
A/llericall Red Cross, Rochil/e, MD) for tile .~elleI'OIIS .~ift of till' /,MEXlleo-sl'-
aFGF lJu/()r miff Ifsc:.!i,1 SII....l!<!CS/;OIlS. Thl' opillions aud ns.H!rl;OIlS cOlllnillcd !terrill nrc
'he prilJnte oues oj ,he nltthol's and nre I10( to fJC cOllstrued as ~fficial or reflre/iug tilt..'
vie",s of tile OIlY Dcpal'/II/em or Ille Nfl/Jfll Service ot Ifl/:~e. This II/fl/Illscrip; II'ns
/,repared by Ullited Sinies CCllJenJlII/!lIt ell/ployees nllll, Ilteriji".c, cnllllnt be (()/,y-
rigilled nlld II/ay bc' wpiedlllitl")//l restrictioll. L.s. IIe1d a Tnliollal Rescnrcll CCI/II/cil
Resl'arrll Associalesllip dllrillS tltc' rellllre o.frllis ",ork. Tllis projectlVas}illlded by rite
Naval Medical Researclt altd Dl'I!elojJlllellt COlllllla/"f, Work Ullil 6/ /53N
MR04·/20.00/-1422.
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